Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rupatadine - Medexus Pharmaceuticals

Next Previous
X
Search
Drug Profile

Rupatadine - Medexus Pharmaceuticals

Alternative Names: Alergoliber; Rupafin; Rupall; Rupatadine fumarate; TK-041; UR 12592

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Uriach
  • Developer Medexus Pharmaceuticals; Teikoku Seiyaku; Uriach
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic urticaria; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Registered Pruritus
  • Discontinued Atopic dermatitis; Dermatitis

Most Recent Events

  • 13 Dec 2018 Pediapharm is now called Medexus Pharmaceuticals
  • 22 Nov 2017 Teikoku Seiyaku and Mitsubishi Tanabe Pharma Corporation intend to launch rupatadine fumarate (Rupafin®) in Japan on November 27, 2017
  • 27 Sep 2017 Registered for Pruritus, Seasonal allergic rhinitis, Perennial allergic rhinitis and Chronic urticaria in Japan (PO, Tablet) (PMDA website)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top